TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
PROK

ProKidney Corp.

Healthcare · Biotechnology

1.60$ -8.1% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

ProKidney Corp. (PROK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 249 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet PROK
Line item Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
17 0.0 0.6 20 40 54 54 532 518 495 484 452 421 388 499 475 441 406 372 352 336 293 249
5.6 4.6 0.2 6.9 27 35 34 519 505 480 466 406 374 340 450 430 396 360 324 300 281 235 190
4.6 4.6 0.2 4.1 21 30 22 506 490 272 244 191 61 84 215 108 99 98 85 95 109 102 75
4.6 4.6 0.2 4.1 21 30 22 506 490 464 446 396 363 329 432 407 358 328 295 272 270 225 182
– – – – – – – – – 5.5 8.1 0.7 1.4 1.9 2.7 5.1 2.4 1.8 1.8 1.2 1.1 1.0 1.0
– – – – – – – – – 11 12 9.4 – – – – – – – – – – –
10 – – – 13 13 13 11 11 12 18 – – – – – – – – – – – –
– – – – – – 0.3 – – – – – – – – – – – – – – – –
0.6 – – 0.5 0.4 0.4 0.0 0.3 0.2 0.2 0.1 0.1 – – – – – – – – – – –
6.8 0.0 0.6 9.5 13 33 47 12 13 14 27 24 29 25 27 31 39 36 33 33 35 30 26
5.5 0.0 0.6 8.4 12 32 46 9.8 11 11 24 21 25 19 21 25 36 33 28 29 31 26 23
0.2 0.0 0.3 0.3 0.3 20 35 0.4 0.5 0.6 0.7 0.7 0.8 1.1 1.0 1.1 0.8 0.9 0.9 1.0 1.1 1.1 1.1
0.8 – – 2.2 2.8 2.5 2.5 3.5 3.0 3.8 2.8 4.5 5.1 3.4 2.9 2.9 3.6 3.1 2.4 1.9 0.9 2.6 1.6
9.9 0.0 0.0 10 27 20 6.5 -1,096 -1,097 -1,602 -1,322 -1,093 -1,103 -1,096 -972 -980 -995 -999 -1,003 -1,008 -1,011 -1,024 -884
-106 0.0 0.0 -148 -162 -229 -251 -1,098 -1,104 -1,623 -1,353 -1,134 -1,140 -1,149 -1,162 -1,180 -1,201 -1,218 -1,234 -1,251 -1,270 -1,290 -1,318
115 32 32 32 32 32 62 62 62 62 65 62 60 61 76 126 128 129 131 135 140 142 187

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?